Logo image of APGE

APOGEE THERAPEUTICS INC (APGE) Stock Price, Quote, News and Overview

NASDAQ:APGE - Nasdaq - US03770N1019 - Common Stock - Currency: USD

35.39  -0.61 (-1.69%)

After market: 35.39 0 (0%)

APGE Quote, Performance and Key Statistics

APOGEE THERAPEUTICS INC

NASDAQ:APGE (8/8/2025, 8:19:14 PM)

After market: 35.39 0 (0%)

35.39

-0.61 (-1.69%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High63.5
52 Week Low26.2
Market Cap2.11B
Shares59.53M
Float41.42M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-11 2025-08-11/bmo
IPO07-14 2023-07-14


APGE short term performance overview.The bars show the price performance of APGE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8 -10

APGE long term performance overview.The bars show the price performance of APGE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40

The current stock price of APGE is 35.39 USD. In the past month the price decreased by -7.21%. In the past year, price decreased by -12.62%.

APOGEE THERAPEUTICS INC / APGE Daily stock chart

APGE Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.7 349.84B
AMGN AMGEN INC 13.22 154.98B
GILD GILEAD SCIENCES INC 15.43 148.54B
VRTX VERTEX PHARMACEUTICALS INC 21.64 94.13B
REGN REGENERON PHARMACEUTICALS 12.34 60.79B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 57.23B
ARGX ARGENX SE - ADR 71.39 40.50B
ONC BEONE MEDICINES LTD-ADR 4.5 31.19B
BNTX BIONTECH SE-ADR N/A 26.84B
SMMT SUMMIT THERAPEUTICS INC N/A 21.28B
INSM INSMED INC N/A 20.78B
NTRA NATERA INC N/A 20.75B

About APGE

Company Profile

APGE logo image Apogee Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2023-07-14. The firm is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.

Company Info

APOGEE THERAPEUTICS INC

221 Crescent St., Building 17, Suite 102B

Waltham MASSACHUSETTS US

Employees: 91

APGE Company Website

APGE Investor Relations

Phone: 16503945230

APOGEE THERAPEUTICS INC / APGE FAQ

What is the stock price of APOGEE THERAPEUTICS INC today?

The current stock price of APGE is 35.39 USD. The price decreased by -1.69% in the last trading session.


What is the ticker symbol for APOGEE THERAPEUTICS INC stock?

The exchange symbol of APOGEE THERAPEUTICS INC is APGE and it is listed on the Nasdaq exchange.


On which exchange is APGE stock listed?

APGE stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for APOGEE THERAPEUTICS INC stock?

15 analysts have analysed APGE and the average price target is 98.69 USD. This implies a price increase of 178.85% is expected in the next year compared to the current price of 35.39. Check the APOGEE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is APOGEE THERAPEUTICS INC worth?

APOGEE THERAPEUTICS INC (APGE) has a market capitalization of 2.11B USD. This makes APGE a Mid Cap stock.


How many employees does APOGEE THERAPEUTICS INC have?

APOGEE THERAPEUTICS INC (APGE) currently has 91 employees.


What are the support and resistance levels for APOGEE THERAPEUTICS INC (APGE) stock?

APOGEE THERAPEUTICS INC (APGE) has a support level at 35.38 and a resistance level at 35.4. Check the full technical report for a detailed analysis of APGE support and resistance levels.


Should I buy APOGEE THERAPEUTICS INC (APGE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does APOGEE THERAPEUTICS INC (APGE) stock pay dividends?

APGE does not pay a dividend.


When does APOGEE THERAPEUTICS INC (APGE) report earnings?

APOGEE THERAPEUTICS INC (APGE) will report earnings on 2025-08-11, before the market open.


What is the Price/Earnings (PE) ratio of APOGEE THERAPEUTICS INC (APGE)?

APOGEE THERAPEUTICS INC (APGE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.6).


What is the Short Interest ratio of APOGEE THERAPEUTICS INC (APGE) stock?

The outstanding short interest for APOGEE THERAPEUTICS INC (APGE) is 22.19% of its float. Check the ownership tab for more information on the APGE short interest.


APGE Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

APGE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to APGE. No worries on liquidiy or solvency for APGE as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

APGE Financial Highlights

Over the last trailing twelve months APGE reported a non-GAAP Earnings per Share(EPS) of -3.6. The EPS increased by 31.49% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.76%
ROE -30.5%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-48.44%
Sales Q2Q%N/A
EPS 1Y (TTM)31.49%
Revenue 1Y (TTM)N/A

APGE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 91% to APGE. The Buy consensus is the average rating of analysts ratings from 15 analysts.


Ownership
Inst Owners134.41%
Ins Owners2.86%
Short Float %22.19%
Short Ratio9.56
Analysts
Analysts90.67
Price Target98.69 (178.86%)
EPS Next Y-35.23%
Revenue Next YearN/A